Hepatotoxicity in Chronic Metabolic Disease: How Diabetes, Immune Activation, and Oxidative Stress Converge to Drive Liver Injury

Chronic metabolic diseases-particularly type 2 diabetes mellitus (T2DM) and the metabolic syndrome-are major drivers of contemporary liver morbidity, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Hepatotoxicity in this context is not a single-pathway event but the outcome of sustained metabolic overload, maladaptive immune activation, and persistent oxidative stress that together create hepatocellular injury, organelle dysfunction, and maladaptive remodeling. This review synthesizes current mechanistic understanding of how hyperglycemia and insulin resistance perturb hepatocyte metabolism, how innate and adaptive immune responses amplify tissue damage, and how oxidative stress both mediates and perpetuates injury through mitochondrial dysfunction, lipid peroxidation, and disruption of antioxidant pathways (e.g., Nrf2). We discuss the role of cytochrome P450 (CYP) enzymes and xenobiotic handling in modifying susceptibility to drug-induced liver injury (DILI) in patients with metabolic disease, summarize emerging biomarkers and mechanistic readouts, and highlight therapeutic strategies targeting the metabolic–immune–oxidative axis. Recognizing the interconnectedness of these processes is essential to improving diagnosis, stratifying risk for hepatotoxic reactions, and developing targeted interventions for liver protection in people with chronic metabolic disease. Keywords: hepatotoxicity, diabetes, oxidative stress, immune activation, cytochrome P450